Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Anthony BalistreriNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-7409-7031
Michael BulaNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-2164-0619
Nicholas J SchorkTranslational Genomics Research Institute, Phoenix, AZ, USA.
Tony S MondalaGenomics Core, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-2809-3187
Steven R HeadGenomics Core, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-5490-2750
Jeffery W KellyNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-8943-3395
Stuart A LiptonNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-3490-1259
Funding
Leadership in AD/ADRD Drug DiscoveryR35AG071734 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2021 to 2025
$5.4M
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's DiseaseR01AG056259 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2021
$3.3M
Aberrant protein S-nitrosylation mediates Gene-Environment Interactions in AD/ADRDU01AG088679 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI STUART A LIPTON, Tomohiro Nakamura · 2024 to 2026
$2.7M
Pharmacologic Lysosomal Flux Activators to Ameliorate Alzheimer's Disease and Related DementiasR01AG073418 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI JEFFERY W KELLY · 2024 to 2026
$2.5M
NRSA Training CoreTL1TR002551 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TEYTON, LUC · 2018 to 2022
Alzheimer's disease (AD) is the most common form of dementia worldwide. Despite extensive progress, the cellular and molecular mechanisms of AD remain incompletely understood, partially due to inadequate disease models. To illuminate the earliest changes in hereditary (familial) Alzheimer's disease, we developed an isogenic AD cerebrocortical organoid (CO) model. Our refined methodology produces COs containing excitatory and inhibitory neurons alongside glial cells, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations, namely PSEN1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Autophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer's disease iPSC-derived cortical organoids. · full record | OpenQuestion